Poor
Poorly Aligned
Patient Risk:
Low
Summary
Overall alignment is poor. The label provided describes parenteral zinc use (zinc chloride) for PN and lacks any data supporting the extracted claims about zinc gluconate lozenges, cold duration, dosing for OTC products, or efficacy by formulation. The majority of claims are unsupported by the label; one claim is contradicted by the label's pregnancy/pediatric information; one claim is partially supported (copper deficiency risk) but with no explicit threshold.
Category Scores
Accurate Statements
Unsupported Statements
Zinc gluconate lozenges can reduce common cold duration by about one-third when taken within 24 hours of symptom onset.
Label provides no information on zinc gluconate lozenges or common cold duration; pertains to parenteral zinc for PN.
Doses of 45-300 mg/day (providing 13-75 mg elemental zinc) showed average reductions of 1-3 days versus placebo.
Label lacks oral dosing data or placebo-controlled cold-duration trials; only parenteral zinc for PN is described.
Effects are dose-dependent.
No dose-response information for zinc lozenges or cold duration is present in the label; focuses on parenteral use.
Effects are strongest early in illness.
Label does not discuss timing of zinc treatment for colds.
Later use shows minimal benefit.
No timing/efficacy data for colds on the label.
Glycine zinc gluconate in lozenges or syrups works best due to direct throat contact.
Label contains no data on glycine zinc gluconate, lozenges, syrups, or throat-contact efficacy.
Glycine zinc gluconate inhibits rhinovirus replication.
No antiviral mechanism data for glycine zinc gluconate in the label.
Tablets are less effective.
No efficacy data by formulation type in the label.
Sprays are less effective.
No efficacy data by delivery form in the label.
Trials used 13-14.7 mg elemental zinc per lozenge.
No lozenge trial data or elemental zinc per lozenge discussed in the label.
Lozenge dosing was taken every 2-3 hours while awake.
No lozenge dosing schedules described in the label.
Up to 100-150 mg/day total.
No daily elemental zinc dosing guidance for lozenges or OTC products in the label.
Non-gluconate forms like zinc acetate match or exceed efficacy in head-to-head studies.
Label has no comparative efficacy data between zinc salts.
A 2017 Cochrane review found zinc gluconate cut cold duration by 33% in adults (2.6 vs. 4.0 days).
No external review data discussed in the label.
Pediatric data is weaker, with no clear benefit under age 7.
Label discusses pediatric use for PN but not efficacy by age for colds.
A 2022 update confirmed reductions but noted high variability.
No 2022 update discussed in the label.
Prasad et al. reported 42% shorter colds.
No trial-specific results in the label.
Mossad et al., 1996 saw 1.6-day reductions.
No trial-specific results in the label.
Bad taste, nausea (20-30% of users), and vomiting limit adherence.
Adverse reactions in the label are listed as 'None known' for the parenteral product; GI taste data not present.
Slow-dissolving lozenges without coatings perform best.
No lozenge dissolution data in the label.
No effect on prevention—daily zinc does not reduce cold incidence.
Label does not address prevention or incidence effects.
Smokers, elderly, or zinc-deficient individuals respond better due to lower baseline levels.
No subgroup efficacy data by smoking status, age, or zinc status in the label.
Viruses beyond rhinovirus (e.g., coronavirus) show inconsistent data.
No broader antiviral data in the label.
Zinc gluconate outperforms zinc sulfate.
No salt-specific comparative data in the label.
Zinc gluconate trails acetate slightly (0.9-day edge).
No salt-by-salt comparative data in the label.
Versus vitamin C: no reliable shortening (Cochrane: 8% reduction at best).
No vitamin C comparison data discussed in the label.
Echinacea or elderberry lack strong evidence for duration cuts.
No evidence discussions for these agents in the label.
Pelargonium sidoides (umckaloabo) rivals zinc in some trials (1-2 day reductions).
No comparative trials with Pelargonium sidoides discussed in the label.
Safe short-term up to 150 mg elemental zinc/day.
Label does not provide a general safety limit for daily zinc; refers to parenteral dosing and monitoring.
Exceeds 40 mg risks copper deficiency long-term.
Label warns copper deficiency with prolonged zinc use but does not specify a 40 mg threshold.
Avoid intranasal zinc—linked to smell loss.
Label discusses intramuscular/intravenous use only; no intranasal zinc information.
FDA deems oral zinc GRAS but flags exaggerated cold claims on labels.
Label does not discuss GRAS status or advertising claims.
Contradictions
Low
AI Statement
Not for pregnant people or kids under 5 without doctor advice.
Label Reference
Pregnancy; Pediatric Use
Important Omissions
Lack of label data on zinc gluconate lozenges, common cold duration claims, and oral/or OTC zinc formulations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The label indicates none known adverse reactions for the parenteral zinc product and provides general pharmacology; extrapolated OTC cold claims are not supported by the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Claims pertain to OTC zinc lozenges and cold duration; the label covers parenteral zinc for PN with no data on lozenges or cold efficacy.
Suggested Improvement
Limit claims to what the label supports; remove or clearly qualify statements about lozenges, dosing, and efficacy for colds; provide explicit caveats about the lack of data for OTC formulations and intranasal zinc; document copper interaction warnings with quantitative thresholds if applicable.